• Here’s your 6-day warning: APC’s ‘Best Practices’ Conference is coming fast

  EduCon is your key to being an effective team member in a well-run compounding operation. Don't miss it! read more →

• PHE to end—and with it—temporary compounding GFIs

  The Covid-19 national and public health emergencies are ending May 11, which means temporary guidance for industry that allowed 503As and 503Bs to prepare 13 COVID drugs for hospitals during the PHE will expire as well. read more →

• When it comes to your financial future, it’s wise to have a plan

  It's time to get a clue about the value of planning now— while you’re young (at heart?)—to assure you have the funds you need to live well into your, um, maturity. read more →

• Maine BOP accepts APC suggestions

  In November 2022, APC submitted comments to Maine Board of Pharmacy on its proposed rule in Chapter 42 regarding compounding drugs for veterinary office use. read more →

• It’s time to take back your profession. On Feb 16, we’ll share our plan.

  Join us on February 16 for a Virtual Town Hall. We will discuss the campaign, as well as the different ways that your involvement will help secure the future of our industry. read more →

• Hole-y expertise, Batman! What to do?

  Last week we surveyed compounders about their knowledge of new laws, regs, and practice protocols. The results are in, and we’re seeing some holes in your expertise. read more →

• Please DON’T attend our 2023 Owner Summit…

  If you’re a pharmacy or facility owner who’s always looking for business-growing ideas and techniques to improve your operations, then APC’s 2023 Owner Summit, March 26-28, is for you. read more →

• FDA’s guidance on compounding ibuprofen isn’t just for 503Bs

  Last Friday, FDA issued guidance on compounding certain ibuprofen oral suspension products... read more →

• Speaking of semaglutide…

  Semaglutide seems to be everywhere. News stories in The Wall Street Journal. Vanity Fair. The New York Times. read more →

More APC News

APC News

Recent entries tagged "fda"